Master Regulator Expression Profiling for Cancer Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods lack effective ways to predict prognosis and tailor treatments based on individual patient-specific gene expression profiles, leading to variable treatment outcomes and potential undertreatment or overtreatment.
Innovation Solution
Measuring the expression levels of master regulators in cancer samples and comparing them to healthy references to identify increased expression indicative of poor prognosis, allowing for personalized treatment strategies and therapeutic guidance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatment methods are used, then treatment can be provided to patients, but treatment outcomes vary and patients may receive undertreatment or overtreatment due to lack of personalized prediction capabilities
Solution Approach 1:
The patent segments the complex cancer treatment decision-making process by identifying and measuring specific master regulator genes (such as MYC, NF-kB, STAT3) that control key cellular processes. Instead of analyzing all genes, the invention focuses on a segmented subset of master regulators that drive cancer progression, making the system more manageable while maintaining predictive accuracy
Solution Approach 2:
The invention changes the parameter being measured from general gene expression profiles to specific master regulator expression levels. By focusing on these key regulatory parameters (transcription factors and signaling molecules), the system achieves reliable prognosis prediction without requiring complex analysis of the entire genome
2Measurement precision
If gene expression profiling of master regulators is implemented, then prognosis prediction accuracy improves, but measurement and analysis complexity increases
Solution Approach 1:
The patent develops a universal assay platform that can measure multiple master regulator genes simultaneously using standardized protocols. This multi-functional approach allows the same measurement system to assess prognosis, predict treatment response, and monitor disease progression across different cancer types, reducing the difficulty of implementation
Solution Approach 2:
The invention uses intermediary molecules such as RNA transcripts of master regulator genes as measurable proxies for the actual protein activity. By measuring RNA expression levels through techniques like qPCR or RNA sequencing, the system indirectly detects the functional state of master regulators without requiring direct protein measurement, simplifying the detection process
3Productivity
If personalized treatment strategies based on master regulator expression are adopted, then patient outcomes improve, but treatment planning complexity increases
Solution Approach 1:
The patent applies local quality by tailoring treatment strategies to the specific master regulator profile of each patient's tumor. Instead of uniform treatment protocols, the system identifies which specific master regulators are overexpressed in each patient and selects targeted therapies that specifically inhibit those pathways, optimizing treatment effectiveness for each individual case
Solution Approach 2:
The invention performs preliminary action by conducting master regulator expression profiling before treatment initiation to predict prognosis and guide therapy selection. This advance characterization allows clinicians to pre-select the most appropriate treatment strategies based on the tumor's molecular profile, avoiding trial-and-error approaches and reducing overall treatment complexity
Data Source
AI summary
Provided herein are methods of assessing, detecting, monitoring the presence, or monitoring progression of cancer in a subject, or assessing or predicting prognosis or survival of a subject having cancer. Also provided are methods of treating cancer based on an increase in the expression of one or more top master regulators of a cancer.